Gastrointestinal Tract Microbiome Dynamics Following Treatment with SER-109, an Investigational Oral Microbiome Therapeutic to Reduce the Recurrence of Clostridium difficile Infection (CDI)

BACKGROUND: Recurrence of CDI occurs within a few weeks after treatment due to antibiotic-induced dysbiosis. SER-109, an investigational, first-in-class microbiome drug, was designed to sustain a clinical response through microbiome restoration with a purified ecology of spores. In an open-label Pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Henn, Matthew, Ford, Christopher, O’Brien, Edward, Wortman, Jennifer, Simmons, Sheri, Diao, Liyang, Litcofsky, Kevin, Bernardo, Patricia, Aunins, John, Cook, David, Trucksis, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630991/
http://dx.doi.org/10.1093/ofid/ofx163.968

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630991/
http://dx.doi.org/10.1093/ofid/ofx163.968

Ejemplares similares